| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
| Targets |
As a chemical linker, m-PEG11-amine does not bind to biological targets. Its functional "targets" are the chemical groups on molecules to which it conjugates. In ADC applications, the linker attaches cytotoxic payloads to monoclonal antibodies through stable covalent bonds. The terminal amine group provides a handle for conjugation to carboxylic acids (via amide bond formation using EDC/HATU activation), activated NHS esters, or carbonyls (via reductive amination). The long PEG11 spacer significantly enhances hydrophilicity and pharmacokinetics, enabling efficient payload attachment and improving the pharmacokinetic properties of ADC therapeutics. This linker does not bind to biological receptors or enzymes but serves as a structural bridge.
|
|---|---|
| ln Vitro |
An ADC cytotoxin is connected to an antibody by use of an ADC linker to form an ADC. Two distinct ligands, one for the E3 ubiquitin ligase and the other for the target protein, are present in PROTAC and are joined by a linker. PROTAC selectively degrades target proteins by taking use of the intracellular ubiquitin-proteasome machinery.
As a synthetic linker molecule, m-PEG11-amine does not exhibit pharmacological activity in cell-based assays. Its in vitro utility is demonstrated through the successful synthesis and characterization of ADC or PROTAC constructs incorporating this linker. Researchers evaluate the linker's performance by assessing conjugation efficiency (via HPLC, LC-MS, or NMR), the stability of resulting conjugates in cell culture media, and the biological activity of final constructs in target cell lines. For PROTACs, target protein degradation is quantified by Western blot or ELISA following treatment of cells with the construct. For ADCs, cytotoxicity is assessed using cell viability assays such as MTT or CellTiter-Glo. The compound is soluble in DMSO (10 mM). |
| ln Vivo |
No direct in vivo pharmacological activity is attributed to m-PEG11-amine itself. Its in vivo relevance is demonstrated through the performance of ADC or PROTAC constructs synthesized using this linker in animal models. For in vivo administration, conjugates are typically formulated in vehicles such as DMSO/PEG300/Tween-80/saline. The linker's stability in biological matrices, its contribution to the construct's pharmacokinetic profile, and its ability to maintain construct integrity are key parameters evaluated in preclinical studies. The long PEG11 spacer significantly enhances hydrophilicity and may prolong circulation time by reducing immunogenicity and protein adsorption.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays are not applicable to m-PEG11-amine as it is a chemical linker with no intrinsic affinity for biological macromolecules. Quality control and characterization are performed using standard analytical methods. Purity is assessed by HPLC (≥95%) and structural integrity is confirmed by ¹H NMR, ¹³C NMR, and mass spectrometry. The amine group content is verified through spectroscopic analysis or titration. For researchers using this linker, conjugation reactions (e.g., amide bond formation) are monitored by TLC, HPLC, or LC-MS. Solubility testing in various solvents is performed to guide formulation development. The compound is soluble in DMSO (10 mM).
|
| Cell Assay |
Cell-based assays are not performed directly on m-PEG11-amine because it is a synthetic linker lacking biological activity. However, the biological activity of ADC or PROTAC constructs containing this linker is evaluated in relevant cell lines. Typical protocols involve treating cells with the construct for 4-48 hours, then assessing target protein degradation (for PROTACs) by Western blot or ELISA, or assessing cytotoxicity (for ADCs) using cell viability assays. Cell viability, proliferation, and apoptosis are monitored using standard assays such as MTT, CCK-8, or flow cytometry. The linker's contribution to the construct's cellular uptake, stability, and efficacy is inferred from comparative studies. DMSO stock solutions are prepared and diluted in cell culture media.
|
| Animal Protocol |
In vivo animal studies are conducted with ADC or PROTAC constructs incorporating m-PEG11-amine, not with the linker alone. Typical protocols utilize rodent models (e.g., mice bearing tumor xenografts). The construct is administered via intravenous, intraperitoneal, or other routes at doses determined by preliminary pharmacokinetic and tolerability studies. Efficacy is assessed by measuring disease progression endpoints such as tumor volume, biomarker levels, or survival. Pharmacodynamic endpoints include target protein degradation (for PROTACs) or tumor growth inhibition (for ADCs). The linker's stability in circulation is evaluated through plasma sampling and LC-MS/MS analysis.
|
| ADME/Pharmacokinetics |
As a chemical linker, m-PEG11-amine does not have a conventional pharmacokinetic profile. However, the pharmacokinetic properties of bioconjugates incorporating this linker are evaluated in preclinical studies. Following administration in rodents, key parameters such as half-life, clearance, volume of distribution, and bioavailability are determined from plasma concentration-time data. The long PEG11 spacer contributes to enhanced aqueous solubility, reduced protein binding, and potentially prolonged circulation time of the conjugate. Linker stability in plasma is assessed by measuring intact conjugate concentrations over time using LC-MS/MS. The compound itself is not administered systemically; therefore, its absorption, distribution, metabolism, and excretion are not independently characterized.
|
| Toxicity/Toxicokinetics |
Toxicological data for m-PEG11-amine are limited because it is a research-grade reagent not intended for human use. Standard laboratory safety precautions should be followed when handling this compound: use of personal protective equipment (gloves, safety goggles, lab coat) and handling in a well-ventilated fume hood. The compound should be stored at 2-8°C for short-term storage or at -20°C for long-term storage (up to 3 years). No genotoxicity, carcinogenicity, or reproductive toxicity data are available. The compound is not classified as a hazardous drug but should be treated with care. Researchers should consult the safety data sheet (SDS) before handling.
|
| References | |
| Additional Infomation |
Additional information for m-PEG11-amine: The compound has a CAS number of 854601-60-8. Its molecular formula is C₂₃H₄₉NO₁₁ and molecular weight is 515.64 g/mol. The IUPAC name is 2,5,8,11,14,17,20,23,26,29,32-undecaoxatetratriacontan-34-amine. Synonyms include m-PEG11-amine, mPEG11-NH2. Purity is typically ≥95-96%. It is a cleavable ADC linker and a PEG-based PROTAC linker. It is for research use only and is not approved for clinical applications. No FDA approvals exist.
|
| Molecular Formula |
C23H49NO11
|
|---|---|
| Molecular Weight |
515.6353
|
| Exact Mass |
515.331
|
| CAS # |
854601-60-8
|
| PubChem CID |
77078255
|
| Appearance |
Colorless to off-white solid-liquid Mixture
|
| LogP |
0.457
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
12
|
| Rotatable Bond Count |
32
|
| Heavy Atom Count |
35
|
| Complexity |
370
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O(CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCN)C
|
| InChi Key |
SWAJVHMMXALQKJ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C23H49NO11/c1-25-4-5-27-8-9-29-12-13-31-16-17-33-20-21-35-23-22-34-19-18-32-15-14-30-11-10-28-7-6-26-3-2-24/h2-24H2,1H3
|
| Chemical Name |
2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanamine
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.9393 mL | 9.6967 mL | 19.3934 mL | |
| 5 mM | 0.3879 mL | 1.9393 mL | 3.8787 mL | |
| 10 mM | 0.1939 mL | 0.9697 mL | 1.9393 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
